Cost analysis of lung cancer management in South Western Sydney

Journal of Medical Imaging and Radiation Oncology

Volumn 56, Issue 2, 2012, Pages 235-241

  Kang, Sharlyn ^a   Koh, Eng Siew ^b,c   Vinod, Shalini K ^b,c   Jalaludin, Bin ^d,e  

^a Illawarra Cancer Care Centre   (Australia)

^b CENTRAL SYDNEY AREA HEALTH SERVICE   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e SYDNEY SOUTH WEST AREA HEALTH SERVICE   (Australia)

Author keywords

Cost analysis; Costs; Lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; NAVELBINE;

ADULT; AGED; ARTICLE; AUSTRALIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CONSULTATION; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE SEVERITY; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICARE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ANTINEOPLASTIC AGENTS; AUSTRALIA; COSTS AND COST ANALYSIS; DIAGNOSTIC IMAGING; FEMALE; HOSPITALIZATION; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL RATE;

EID: 84859790212     PISSN: 17549477     EISSN: 17549485     Source Type: Journal    
DOI: 10.1111/j.1754-9485.2012.02354.x     Document Type: Article

References (24)

1. Australian Institute of Health and Welfare (AIHW). Health system expenditures on cancer and other neoplasms in Australia, 2000-1. Health and Expenditure Series no.22, Cat No. HWE 29. Canberra: AIHW. 2005.
2. Tracey E, Baker D, Chen W, Stavrou E, Bishop J. Cancer in the New South Wales: Incidence, Mortality and Prevalence Report 2005. Cancer Institute of NSW, Sydney, 2007; 11-5.
3. Bosanquet N, Sikora K. The economics of cancer care in the UK. Lancet 2004; 5: 568-74. (Pubitemid 39194046)
4. Reeder C, Gordon D. Managing oncology costs. Am J Manag Care 2006; 12 (1): S3-15.
5. Shih YCT, Halpern M. Economic evaluations of medical interventions for cancer patient: how, why, and what does it mean? CA Cancer J Clin 2008; 58: 231-24.
6. Rosenthal MA, Webster PJ, Gebski VJ, Stuart-Harris RC, Langlands AO, Boyages J. The cost of treating small cell lung cancer. Med J Aust 1992; 156: 605-10.
7. Evans WK, Will BP, Berthelot JM, Wolfson MC. The economics of lung cancer management in Canada. Lung Cancer 1996; 14: 19-29. (Pubitemid 26079511)
8. Oliver E, Killen J, Kiebert G et al. Treatment pathways, resource use and costs in the management of small cell lung cancer. Thorax 2001; 56: 785-90. (Pubitemid 32917549)
9. Chouaïd C, Molinier L, Combescure C, Daurès JP, Housset B, Vergnenègre A. Economics of the clinical management of lung cancer in France: an analysis using a Markov model. Br J Cancer 2004; 90: 397-402. (Pubitemid 38250635)
10. Dedes KJ, Szuucs TD, Bodis S et al. Management and costs of treating lung cancer patients in a university hospital. Pharmacoeconomics 2004; 22 (7): 435-44. (Pubitemid 38736878)
11. Kutikova L, Bowman L, Chang S, Long SR, Obasaju C, Crown WH. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer 2005; 50: 143-54. (Pubitemid 41427890)
12. Demeter SJ, Jacobs P, Chmielowiec C et al. The cost of lung cancer in Alberta. Can Respir J 2007; 14 (2): 81-6. (Pubitemid 46730798)
13. Fleming I, Monaghan P, Gavin A, O'Neill C. Factors influencing hospital costs of lung cancer patients in Northern Ireland. Eur J Health Econ 2008; 9: 79-86.
14. Pompen M, Gok M, Novák A et al. Direct costs associated with the disease management of patients with unresectable advanced non-small cell lung cancer in The Netherlands. Lung Cancer 2009; 64: 110-6.
15. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111 (6): 1710-7. (Pubitemid 27260107)
16. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973; 4: 31-42.
17. Australian Government Department of Health and Ageing. Medicare benefits schedule November 2005. Commonwealth of Australia. 2005.
18. Australian Government Department of Health and Ageing. Schedule of pharmaceutical benefits for approved pharmacists and medical practitioners. Operative from 1 December 2005. Commonwealth of Australia. 2005.
19. Australian Commonwealth Department of Health and Aged Care. The Australian health care system: an outline. Commonwealth of Australia. 2000.
20. Chouaïd C, Atsou K, Hehblum G, Vergnenègre A. Economics of treatments for non-small cell lung cancer. Pharmacoeconomics 2009; 27 (2): 113-25.
21. Vinod SK, O'Connell DK, Simonella L et al. Gaps in optimal care of lung cancer. J Thorac Oncol 2008; 3: 871-9.
22. Stevens W, Stevens G, Kolbe J et al. Lung cancer in New Zealand: patterns of secondary care and implications for survival. J Thorac Oncol 2007; 2 (6): 481-93. (Pubitemid 47189283)
23. Access Economics Pty Limited for the Cancer Council NSW. Cost of cancer in NSW. 2007; v-xii.
24. Will BP, Berthelot JM, Nobrega KM, Flanagan W, Evans WK. Canada's Population Health Model (POHEM): a tool for performing economic evaluations of cancer control interventions. Eur J Cancer 2001; 37: 1797-804. (Pubitemid 32817055)